Renoprotective effects of antihypertensive drugs

American Journal of Hypertension

Volumn 12, Issue 1 SUPPL. 1, 1999, Pages 19S-32S

  Preston, Richard A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive drugs; Renal disease; Renoprotection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; MINOXIDIL; NISOLDIPINE; RAMIPRIL; SODIUM ION; THIAZIDE DIURETIC AGENT; VERAPAMIL;

BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MICROALBUMINURIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SODIUM EXCRETION; SODIUM RESTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; SODIUM;

EID: 0033020275     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00210-6     Document Type: Article

References (107)

1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI): The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-2444.
2. Perry HM Jr, Miller JP, Fornoff JR, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
3. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. New Engl J Med 1996;334:13-18.
4. Klag MJ, Whelton PK, Randall BL, et al: End-stage renal disease in African-American and white men. 16 year MRFIT findings. JAMA 1997;277:1293-1298.
5. Perneger TV, Whelton PK, Klag MJ: History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997;15:451-456.
6. Whelton PK, He J, Perneger TV, Klag MJ: Kidney damage in "benign" essential hypertension. Curr Opin Nephrol Hyperens 1997;6:177-183.
7. Whelton PK, Perneger TV, He J, Klag MJ: The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Human Hyperens 1996;10:683-689.
8. Walker WG: Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993;22:164-173.
9. Ruilope LM, Campo C, Rodriguez-Artalejo F, et al: Blood pressure and renal function: therapeutic implications. J Hypertens 1996;14:1259-1263.
10. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-1080.
11. Preston RA, Singer I, Epstein M: Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 1996;154:637-642.
12. Preston RA, Epstein M: Hypertension and renal parenchymal disease. Semin Nephrol 1995;15:138-151.
13. Smith MC, Dunn MJ: Hypertension associated with renal parenchymal disease, in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney. Little Brown and Company, Boston, 1997, pp 1333-1365.
14. Smith MC, Dunn MJ: Hypertension in renal parenchymal disease, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, Ltd., New York, 1995, pp 2081-2082.
15. Preston RA, Epstein M: Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997;15:1365-1377.
16. Greco BA, Breyer JA: Atherosclerotic ischemic renal disease. Am J Kidney Dis 1997;29:167-187.
17. Pohl MA: Renal artery stenosis, renal vascular hypertension, and ischemic nephropathy, in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney. Little Brown and Company, Boston, 1997, pp 1367-1423.
18. Campese VM: Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 1994; 23:531-550.
19. Frohlich ED, Tarazi RC, Dustan HP: Hemodynamic and functional mechanisms in two renal hypertensions: arterial and pyelonephritis. Am J Med Sci 1971; 261:189-195.
20. Valvo E, Gammaro L, Bedogna V, et al: Hypertension in polycystic kidney disease. Contrib Nephrol 1987;54: 95-102.
21. Valvo E, Gammaro L, Bedogna V, et al: Hypertension in primary immunoglobulin A nephropathy (Berger's disease): hemodynamic alterations and mechanisms. Nephron 1987;45:219-233.
22. Kim KE, Onesti G, Schwartz AB: Hemodynamics of hypertension in chronic/end-stage renal disease. Circulation 1972;46:456-464.
23. Haddy FJ, Buckalew VM: Endogenous digitalis-like factors in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, Ltd., New York, pp 1055-1067.
24. Hamlyn JM, Manunta P, Hamilton BP: Endogenous Oubain in the pathogenesis of hypertensive and cardiovascular disorders, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, Ltd., New York, 1995, pp 1069-1081.
25. National High Blood Pressure Education Program Working Group: 1995 update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996;156:1938-1947.
26. Zeman FJ: Clinical Nutrition and Dietetics Second Edition. Macmilliam Publishing Company, New York, 1991, pp 792-804.
27. Greger R, Dillingham MA, Schrier RW: Mechanism of diuretic action, in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney. Little Brown and Company, Boston, 1997, pp 2321-2341.
28. Lowenthal DT, Dickerman D: The use of diuretics in varying degrees of renal impairment: an overview. Clin Exp Hypertens 1983;A5:297-307.
29. Rose BD: Diuretics. Kidney Int 1991;39:336-352.
30. Epstein M, Materson BJ: Furosemide, in Messerli FH (ed): Cardiovascular Drug Therapy. W.B. Saunders, Philadelphia, 1990, pp 318-336.
31. Brater DC, Voelker JR: Use of diuretics in patients with renal disease, in Bennett WM, McCarron DA (eds): Contemporary Issues in Nephrology, Vol 17: Pharmacotherapy of Renal Diesase and Hypertension. Churchill Livingstone, New York, 1987, pp 115-147.
32. Voelker JR, Cartwright-Brown D, Anderson S, et al: Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987;32:572-578.
33. Brater DC: Use of diuretics in chronic renal insufficiency and nephrotic syndrome. Semin Nephrol 1988; 8:333-341.
34. Oster JR, Epstein M, Smoller S: Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983;99:405-406.
35. Striker GE, Klahr S: Clinical trials in the progression of renal failure. Adv Intern Med 1997;42:555-593.
36. Striker GE: Report on a workshop to develop managment recommendations for the prevention of progression in chronic disease Bethesda (MA) April 1994. Nephrol Dial Transplant 1995;10:290-292.
37. Jacobson HR, Striker GE: Report on a workshop to develop management recommendations for the prevention of progression in chronic disease. Am J Kidney Dis 1995;25:103-106.
38. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
39. Gansevoort RT, Navis GJ, Wapstra FH, et al: Proteinuria and progression of renal disease: therapeutic implications. Curr Opin Nephrol Hypertens 1997;6:133-140.
40. El Nahas AM: Progression of renal scarring: a balancing act. Adv Nephrol 1998;27:67-84.
41. Mackenzie HS, Brenner BM: Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998;31:161-170.
42. Neuringer JR, Brenner BM: Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Dis 1993;22:98-104.
43. Dunn BR, Anderson S, Brenner BM: The hemodynamic basis of renal disease. Semin Nephrol 1986;6: 122-138.
44. Remuzzi G, Benigni A: Progression of proteinuric diabetic and nondiabetic renal disease: a possible role for endothelin. Kidney Int 1997;51(suppl 58):S66-S68.
45. Kohan DE: Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis 1993;22:493-510.
46. Simonsen MS, Dunn MJ: Endothelin peptides and the kidney. Annu Rev Physiol 1993;55:249-265.
47. Perico N, Remuzzi G: Role of endothelin in glomerular injury. Kidney Int 1993;43(suppl 39):S76-S80.
48. Perico N, Remuzzi G: Vascular endothelin and renal disease progression, in Berlyn GM (ed): The Kidney Today. Selected Topics in Renal Science, Vol 100, Contributions to Nephrology. Karger, Basel, 1992, pp 236-253.
49. Ohta K, Hirata Y, Schichiri M, et al: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307-311.
50. Saito Y, Kazuwa N, Shirakami G, et al: Endothelin in patients with chronic renal failure. J Cardiovascular Pharmacol 1991;17(suppl 7):S437-S439.
51. Deray G, Carayon A, Maistre G, et al: Endothelin in chronic renal failure. Nephrol Dial Transplant 1992;7: 300-305.
52. Clozel M, Breu V, Burri K, et al: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:259-261.
53. Clozel M, Breu V, Gray GA, Löffler B-M: Pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993; 22(suppl 8):S377-S379.
54. Klahr S, Levey A, Beck GJ, et al: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-884.
55. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123:754-762.
56. Klahr S, Breyer JA, Beck GA, et al: Dietary protein restriction and blood pressure control on the progression of polycystic kidney disease. J Am Soc Nephrol 1995;5:2037-2047.
57. Anderson S, Meyer TW: Pathophysiology and adaptation in chronic renal failure, in Schrier RW, Gottschalk (eds): Diseases of the Kidney. Little Brown and Company, Boston, 1997, pp 2555-2579.
58. Anderson S: Antihypertensive therapy in experimental diabetes. J Am Soc Nephrol 1992;3(4, suppl):S86-S90.
59. Ishidoya S, Morrissey J, McCracken R: Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Intern 1996;49:1110-1119.
60. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
61. Laffel LMB, McGill J, Gans D: The beneficial effects of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99: 497-503.
62. Ravid M, Savin H, Jutrin I, et al: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118: 577-581.
63. Ravid M, Savin H, Jutrin I, et al: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Intern 1994;45(S45): S161-S164.
64. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-289.
65. Materson BJ: ACE inhibitors as a shield against diabetic nephropathy. Arch Intern Med 1996;156:239-240.
66. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
67. The Gisen Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-1863.
68. Ruggenenti A, Perna L, Mosconi M, et al: The angiotensin-converting enzyme inhibitor ramipril slows the rate of GFR decline and the progression to end stage renal failure in proteinuric, non-diabetic chronic renal disease. J Am Soc Nephrol 1997;8A:147.
69. Uhle BU, Whitworth JA, Shahinfar S, et al: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996;27:489-495.
70. Giatras I, Lau J, Levey AS, et al for the Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-345.
71. Navis G, se Jong PE, de Zeeuw D: Optimizing the rnal response to ACE inhibition: a strategy toward more effective long-term renoprotection. Adv Nephrol 1998;27:57-66.
72. Heeg JE, de Jong PE, van der Hem GK, et al: Efficacy and variability of the antiproteinuric effect of lisinopril. Kidney Int 1989;36:272-279.
73. Heeg JE, de Zeeuw D, de Jong PE: The effects of lisinopril on renal hemadynamics in patients with renal disease. Curr Opin Cardiol 1989;4:29S-34S.
74. Gansevoort RT, de Zeeuw D, de Jong PE: Dissociation between the course of the hemodynamic and the antiproteinuric effects of ACE inhibition. Kidney Int 1993;44:579-584.
75. Navis GJ, de Jong PE, Donker AJM, et al: Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987;31:815-819.
76. Epstein M: Calcium antagonists and the kidney: implications for renal protection. Chapter 24, in Epstein M (ed): Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia, 1997, pp 433-565.
77. Parving HH, Tarnow L, Rossing P: Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens 1996;14(suppl 40):S21-S25.
78. Epstein M, Cooper M: Diabetic nephropathy: focus on ACE inhibition and calcium channel blockade. Chapter 14, in Epstein M (ed): Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia 1997, pp 243-271.
79. Hyashi K, Saruta T, Epstein M: Renal hemodynamic effects of calcium antagonists. Chapter 22, in Epstein M: Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia 1997, pp 393-411.
80. Oates JA: Antihypertensive agents and the drug therapy of hypertension, in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Bilman AG (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Macmillan Publishing Co., New York, 1996, pp 780-808.
81. Schultz P, Raij L: Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990;15(suppl 1):76-80.
82. Makrilakis K, Bakris GL: Calcium antagonists: are they all created equal in regard to slowing progression diabetic nephropathy? Chapter 15, in Epstein M (ed): Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia, 1997, pp 393-411.
83. Smith AC, Toto R, Bakris GL: Differences in glomerular membrane permeability responses to a nodihydropyridine (NDHP) and dihydropyridine (DHP) calcium channel antagonist (CCRC) in patients with diabetic nephropathy: a randomized single-blind, two-year study. J Am Soc Nephrol 1997;8:A562.
84. Bohlen L, de Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:84S-92S.
85. Rossing P, Tarnow L, Boelskifte S, et al: Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997;46:481-487.
86. Velussi M, Brocco E, Frigato F, et al: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996 Feb;45:216-222.
87. Zucchelli P, Zuccala A, Borghi M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42: 452-458.
88. Bakris GL, Copley JB, Vicknair N, et al: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
89. Epstein M, Waeber B: Fixed-dose combination therapy with calcium antagonists. Chapter 26, in Epstein M (ed): Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia, 1997, pp 493.
90. Epstein M, Bakris GL: Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156:1969-1978.
91. Letellier P, Overlack A, Agnes E, Desche P: Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. J Hum Hypertens 1994;8: 145-149.
92. DeLeeuw PW, Kroon AA: Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension. J Hypertens 1997;15:39-42.
93. Gradman AH, Cutler NR, Davis PJ, et al: Combined enalapril and feldipine extended release (ER) for systemic hypertension. Am J Cardiol 1997;79:431-435.
94. Tunon J, Tarin N, Egido J: Effects of calcium antagonists on vasoactive hormones. Chapter 23, in Epstein M (ed): Calcium Antagonists and Clinical Medicine. Hanley & Belfus, Philadelphia, 1997, pp 413-432.
95. Epstein M: The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed dose combination antihypertensive therapy. Renal Failure 1996;18:813-832.
96. Ritz E, Orth SR, Strzelczk P: Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997;15(suppl 2):S2-S26.
97. Brown SA, Walton CL, Crawford, P, Bakris GL: Long term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;36: 526-536.
98. Bakris GL, Barnhill BW, Sadler R: Treatment of hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912-919.
99. Bakris GL, Copley JB, Vicknair N, Leurgans S: Effects of nondihydropyridine calcium antagonists on progression of nephropathy resulting from noninsulin dependent diabetes mellitus: a five year follow-up prospective study. J Invest Med 1995;43: 440A.
100. Bakris GL, Weir MR, DeQuattro V, et al: Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolopril, or calcium antagonist, verapamil, alone or in fixed-dose combination in patients with diabetic nephropathy: a randomized multicentered study. J Am Soc Nephrol 1996;7:1546.
101. Messerli FH, Weber MA, Brunner HR: Angiotensin II Receptor inhibition. A new therapeutic principle. Arch Intern Med 1996;156:1957-1965.
102. Goodfriend TL, Elliot ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996;334: 1649-1654.
103. Chan JCN, Critchley JAJH, Tomlinson B, et al: Antihypertensive and antialbuminuric effects of losartan postassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:72-80.
104. Ziai F, Ots M, Provoost AP, et al: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50(suppl 57):S132-S136.
105. Kohzuki M, Yasujima M, Liu PF, et al: Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharmacol Physiol 1995;(suppl 1):S366-S367.
106. Gansevoort RT, de Zeeuw D, Shahinfar S, et al: Effect of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12(suppl 2):S37-S42.
107. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference with the renin-angiotensin system? Kidney Int 1994;45:861-867.